Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela Resch

Physician Assistant Leavenworth, KS Physician Assistant

NPI 1598748386 CMS profile 10735957

3550 S 4Th St, Ste 200, Leavenworth, KS 66048

Open in the dashboard

General payments

$10,163

624 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Resch of Leavenworth, KS is reported in the CMS Open Payments database as having received $10,163 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,057 125
2024 General $1,887 108
2023 General $1,845 110
2022 General $2,155 135
2021 General $2,218 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Resch
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Angela Resch were reported at $2,057. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Angela Resch Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,218 $132 $37–$438 $132
2022 $2,155 $155 $48–$522 $149
2023 $1,845 $167 $52–$557 $160
2024 $1,887 $178 $55–$600 $164
2025 $2,057 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,694 110 payments
  2. Lilly USA, LLC $900 51 payments
  3. AstraZeneca Pharmaceuticals LP $737 41 payments
  4. Pfizer Inc. $713 59 payments
  5. Novo Nordisk Inc $654 43 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $542 33 payments
  7. Amgen Inc. $431 27 payments
  8. Astellas Pharma US Inc $394 15 payments
  9. Otsuka America Pharmaceutical, Inc. $307 16 payments
  10. Abbott Laboratories $288 14 payments
  11. Other $3,502 215 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,073 623 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $837 45 payments
  2. UBRELVY $618 44 payments
  3. XIFAXAN $542 33 payments
  4. NURTEC ODT $456 42 payments
  5. Ozempic $450 28 payments
  6. RYBELSUS $413 26 payments
  7. FARXIGA $385 19 payments
  8. MOUNJARO $356 18 payments
  9. QULIPTA $348 23 payments
  10. REXULTI $307 16 payments
  11. Other $8,280 527 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 146 drugs

Part D claims

8,899

Median for Physician Assistant: 241

Drug cost

$643,954

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 155 $160,579
Eliquis Apixaban Brand 82 $67,110
Trulicity Dulaglutide Brand 50 $53,796
Mounjaro Tirzepatide Brand 43 $43,840
Januvia Sitagliptin Phosphate Brand 34 $27,734
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $27,493
Jardiance Empagliflozin Brand 38 $20,651
Lurasidone Hcl Generic 20 $19,902
Linzess Linaclotide Brand 19 $19,389
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 27 $17,066

The 10 drugs with the highest cost, of 146 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $140
$140 — —
JARDIANCE
  • Lilly USA, LLC $70
  • Boehringer Ingelheim Pharmaceuticals, Inc. $55
$125 38 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $104
$104 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $89
$89 — —
Auvelity
  • Axsome Therapeutics, Inc. $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record